Mereo BioPharma Group plc

Transaction in Own Shares • Oct 12, 2020

National Storage Mechanism | Additional information

RNS Number : 8185B

Mereo BioPharma Group plc

12 October 2020

Mereo BioPharma Group plc

PDMR Notification

London and Redwood City, Calif., October 12, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on October 09, 2020, Charles Sermon, General Counsel at Mereo, purchased 18,405 American Depositary Shares (ADSs) at a price of USD 2.41 per ADS.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

1

Details of the person discharging managerial responsibilities

a)

Name

Charles Sermon

2

Reason for the notification

a)

Position/status

General Counsel

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

Price(s)	Volume(s)
USD 2.41	18,405

d)

Aggregated information:  volume, Price

e)

Date of the transaction

2020-10-09

f)

Place of the transaction

XNMS (Nasdaq Global Market)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBDBDGBSBDGGD